Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: Clin Cancer Res. 2018 Mar 7;24(11):2616–2630. doi: 10.1158/1078-0432.CCR-17-1207

Figure 5. Suppression of TAZ inhibits aRMS tumor growth and prolongs survival in murine xenografts.

Figure 5.

TAZ suppression in Rh28 xenografts (A) delays tumor progression, as measured by time to maximum tumor burden, and (B) prolongs survival as measured by Kaplan-Meier survival plot. Median survival and 95% confidence interval for the groups were: Suc sh2 (17.5 ± 0.98 days), Dox sh2 (33 ± 3.49 days), Suc sh5 (17.5 ± 2.47 days), and Dox sh5 (30 ± 3.39 days). (C) qRT-PCR validation of TAZ suppression and downregulation of TAZ target genes (CTGF, CYR61). (D) Representative IHC images of H&E, TAZ, Ki67, and TUNEL staining for each of the groups. IHC quantitation showing the TAZ shRNA groups have (E) decreased nuclear TAZ staining, (F) decreased proliferation (Ki67), and (G) increased apoptosis (TUNEL). Scale bars: 100μm. N=4 in each arm except Dox TAZ_sh5 group, where one mouse did not develop a tumor so N=3.